Positive expression of p53, c-erbB2 and MRP proteins is correlated with survival rates of NSCLC patients

Yujin Xu, Liancong Wang, Xiao Zheng, Guan Liu, Yuezhen Wang, Xiaojing Lai, Jianqiang LiMolecular 2013 · DOI

Abstract

The incidence of lung cancer is one of the leading causes of mortality. This study aimed to investigate the prognostic and predictive importance of p53, c-erbB2 and multidrug resistance proteins (MRP) expression and its correlation with clinicopathological characteristics of patients with non-small cell lung cancer (NSCLC). Expression of p53, c-erbB2 and MRP proteins in 152 tumor samples from resected primary NSCLCs was detected by immunohistochemical staining. The correlation of proteins, survival and clinicopathological characteristics was investigated in 152 patients undergoing potentially curative surgery. The positive rates of p53, c-erbB2 and MRP expression were 53.9 (82/152), 44.1 (67/152) and 43.4% (66/152), respectively. Overall survival rates of patients were markedly correlated with the overexpression of p53, c-erbB2 and MRP proteins. One, 2- and 3-year survival rates of patients exhibiting a positive expression of these proteins were 72.6, 54.8 and 32.2%, respectively. These rates were lower compared with those of patients with a negative expression of these proteins (92.1, 78.5 and 63.4%) (P=0.02, 0.01 or 0.00, respectively). Results of Cox's regression analysis showed that c-erbB2 expression and cell differentiation were independent prognostic factors in patients with NSCLC. These findings suggest that the positive expression of p53, c-erbB2 and MRP proteins is correlated with the survival rates of NSCLC patients. Detection of positive p53, c-erbB2 and MRP expression may be a useful predictive indicator of prognosis. Positive c-erbB2 expression is an independent prognostic factor, with a potential to be used as a predictive indicator of chemotherapy efficacy in NSCLC patients.

Introduction

Non-small cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancer cases. Despite advances in surgical techniques for early-stage (I-IIIa) disease, the overall cure rate remains low at approximately 13%, with 30–60% of patients experiencing recurrence or metastasis following surgery. A major factor contributing to treatment failure is Multidrug Resistance (MDR), where tumor cells develop mechanisms to evade the effects of chemotherapy. This study evaluates the expression of three key proteins—p53, c-erbB2, and multidrug resistance proteins (MRP)—to determine their combined prognostic value and correlation with clinical outcomes in NSCLC patients.

Methods

The study cohort consisted of 152 patients with pathologically confirmed NSCLC who underwent surgery in Zhejiang, China. Patients had not received prior radiotherapy or chemotherapy. Tumor samples were analyzed using Immunohistochemistry (IHC) with the Streptavidin-Peroxidase (S-P) method.

  • Protein Expression Analysis: p53 expression was quantified based on the percentage of nucleus-stained cells. MRP and c-erbB2 expression levels were determined using the FDA-recommended Hercep score.
  • Statistical Evaluation: Survival rates were estimated using Kaplan-Meier curves. Multivariate analysis via Cox’s proportional hazards regression was performed to identify independent prognostic factors among clinicopathological variables and protein expression levels.

Results

The positive expression rates for p53, c-erbB2, and MRP were 53.9%, 44.1%, and 43.4%, respectively. The study found significant correlations between these markers and patient survival.

Immunohistochemical staining of p53 (A), c-erbB2 (B), and MRP (C) in NSCLC tissues.

Survival Correlation

Patients expressing p53, c-erbB2, or MRP had significantly lower survival rates compared to those with negative expression. The 3-year survival rate for "triple positive" patients was 32.2%, whereas "triple negative" patients achieved a 63.4% survival rate (P < 0.01).

Independent Prognostic Factors

Multivariate analysis revealed that c-erbB2 expression and the degree of cell differentiation were independent prognostic factors. This highlights c-erbB2 as a particularly potent biomarker for identifying high-risk patients. Additionally, MRP expression was found to be significantly higher in lung adenocarcinomas (67.6%) than in squamous cell carcinomas (33.0%), suggesting histological differences in drug resistance mechanisms.

Conclusion

The positive expression of p53, c-erbB2, and MRP proteins is strongly correlated with reduced survival in NSCLC patients. These markers, particularly c-erbB2, serve as valuable predictive indicators of prognosis and chemotherapy efficacy. Future research should investigate the molecular pathways through which these proteins interact to drive multidrug resistance and explore targeted therapies to improve outcomes for this patient subgroup.

Summary updated

Abstract

The incidence of lung cancer is one of the leading causes of mortality. This study aimed to investigate the prognostic and predictive importance of p53, c-erbB2 and multidrug resistance proteins (MRP) expression and its correlation with clinicopathological characteristics of patients with non-small cell lung cancer (NSCLC). Expression of p53, c-erbB2 and MRP proteins in 152 tumor samples from resected primary NSCLCs was detected by immunohistochemical staining. The correlation of proteins, survival and clinicopathological characteristics was investigated in 152 patients undergoing potentially curative surgery. The positive rates of p53, c-erbB2 and MRP expression were 53.9 (82/152), 44.1 (67/152) and 43.4% (66/152), respectively. Overall survival rates of patients were markedly correlated with the overexpression of p53, c-erbB2 and MRP proteins. One, 2- and 3-year survival rates of patients exhibiting a positive expression of these proteins were 72.6, 54.8 and 32.2%, respectively. These rates were lower compared with those of patients with a negative expression of these proteins (92.1, 78.5 and 63.4%) (P=0.02, 0.01 or 0.00, respectively). Results of Cox's regression analysis showed that c-erbB2 expression and cell differentiation were independent prognostic factors in patients with NSCLC. These findings suggest that the positive expression of p53, c-erbB2 and MRP proteins is correlated with the survival rates of NSCLC patients. Detection of positive p53, c-erbB2 and MRP expression may be a useful predictive indicator of prognosis. Positive c-erbB2 expression is an independent prognostic factor, with a potential to be used as a predictive indicator of chemotherapy efficacy in NSCLC patients.
BibTeX
@inproceedings{xu2013positive,
  author = {Yujin Xu and Liancong Wang and Xiao Zheng and Guan Liu and Yuezhen Wang and Xiaojing Lai and Jianqiang Li},
  title = {{Positive expression of p53, c-erbB2 and MRP proteins is correlated with survival rates of NSCLC patients}},
  booktitle = {Molecular},
  year = {2013},
  doi = {10.3892/mco.2013.72},
}
Figure